Categories: HealthcareNews

Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise

SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ — The life sciences industry is buzzing about AI’s potential to transform drug discovery. But at this year’s J.P. Morgan Healthcare Conference, the real conversation isn’t about finding the perfect algorithm — it’s about fixing the ecosystem that makes AI work.

That’s the message Zifo — a leading global enabler of AI and data-driven enterprise informatics for science-driven organizations — is taking to San Francisco next week.

As biopharma companies face growing pressure to show returns on their massive tech investments, Zifo wants to make one thing clear: buying Technology is relatively the easy part. The real challenge lies in the other three pillars of the lab — Process, Data, and Organization (PDOT).

Also known as the ‘Super Bowl of Biotech,’ the J.P. Morgan conference brings together the most influential voices in healthcare to shape the future of investment. This year, the agenda signals a major shift: moving beyond shiny innovation to the hard work of making it operational.

Representing Zifo will be Narasimhan Aravamudhan, VP of Scientific Data for AI, and Kannan Jagamoorthy, VP and GM for the Americas. Their message? The industry’s move toward ‘Agentic AI’ — systems that can plan and execute tasks on their own across the scientific value chain — will stall unless companies embrace a holistic PDOT strategy.

“Successful AI adoption isn’t just about impressive demos — it’s about disciplined execution. At Zifo, we help leaders strengthen their scientific processes and data foundations, so their technology investments deliver real value. It starts with identifying the right use case and ensuring every step is built for success,” said Narasimhan, a recognized AI expert who leads Zifo’s AI strategy known as the ‘Practical AI’ program.

The presence of Kannan Jagamoorthy, based locally in the San Francisco Bay Area, highlights the ‘Organization’ component of the framework — specifically the human side of technology adoption.

“Technology doesn’t solve problems; people using technology solve problems,” says Kannan, who heads Zifo in North America. “Our clients are moving from exploration to scaling. The winners in 2026 will be the ones that treat PDOT as a single, unified strategy — not four separate silos.”

During the conference, Zifo’s leadership will share how PDOT makes AI work in practice:

  • Process and Data: Laying the foundation for agentic systems that need clean, standardized inputs to act autonomously.
  • Organization: Managing the human side of change so scientists trust and use the new tools.
  • Technology: Connecting physical lab automation with digital AI strategies to create the ‘Lab of the Future.’

About Zifo

Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. https://zifornd.com/; https://zifornd.com/practical-ai-blueprints/

Logo: https://healthtechnologynet.com/wp-content/uploads/2026/01/Zifo_Technologies_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/zifo-at-jpm-healthcare-conference-2026-why-technology-alone-cannot-deliver-the-ai-promise-302656459.html

SOURCE Zifo Technologies

Staff

Recent Posts

Understanding When to Use Fillers or Neurotoxins According to Dr. Ran Rubinstein

Dr. Ran Rubinstein discusses how individualized treatment planning determines when fillers, neurotoxins, or collagen-stimulating injectables…

1 hour ago

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the…

1 hour ago

Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial…

1 hour ago

ALX Oncology Announces Pricing of Underwritten Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX…

1 hour ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Company expects up to six-month review period per FDA guidelines  New longer-term clinical data demonstrating…

1 hour ago